I. Mirsky et al., CONTRACTILE STATE IS THE MAJOR DETERMINANT OF FUNCTIONAL OUTCOME IN PATIENTS WITH LEFT-VENTRICULAR DYSFUNCTION TREATED WITH ENALAPRIL, European heart journal, 16(6), 1995, pp. 808-817
Large-scale drug trials have focused primarily an mortality and morbid
ity and less on the functional state of the myocardium. A model was de
veloped to assess myocardial contractile state in patients with left v
entricular. (LV) dysfunction and to address the questions of differenc
es in function between patients with and without overt heart failure,
effects of enalapril, and best predictors of functional outcome. Press
ure-angiographic data were obtained from 16 patients with overt heart
failure and 47 without heart failure. Repeat studies were conducted in
41 patients following I year's treatment with enalapril or placebo. L
eft ventricular silhouettes were divided into 18 segments to estimate
regional ejection fraction, wall stress and myocardial damage (% myoca
rdial damage). Contractile state was assessed and ranked by ejection r
ate-preload-afterload relationships and by a score method based on 10
myocardial and ventricular function parameters. End-diastolic and end-
systolic volumes (EDV, ESV) were significantly greater (P<0.001), ejec
tion fraction (EF) lower (P<0.009), % myocardial damage greater (P<0.0
08) and contractile state more depressed in patients with overt heart
failure. Changes in EDV and ESV (Delta placebo vs Delta enalapril) wer
e significant (Delta EDV, P<0.003, Delta ESV, P<0.014). Directional sh
ifts in the diastolic pressure-volume relationships with enalapril or
placebo depended primarily on the basal contractile stare and diastoli
c volume range. The best single predictors of post-treatment EF were t
he score index (a surrogate parameter for the contractile state) and E
S V. Added benefits of enalapril include the prevention of further dil
atation in patients with less depressed contractile state and delay in
the onset of heart failure. Asymptomatic patients with LV dysfunction
should also be considered for angiotensin converting enzyme (A CEI in
hibitor therapy.